Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.

Published online

Journal Article (Review)

Dabigatran is effective in decreasing the risk of ischaemic stroke in patients with atrial fibrillation. However, like all anticoagulants, it is associated with a risk of bleeding. In cases of trauma or emergency surgery, emergency reversal of dabigatran-induced anticoagulation may be required. A specific reversal agent for dabigatran, idarucizumab, has been approved by the US Food and Drug Administration. Alternative reversal agents are available, such as prothrombin complex concentrates (PCCs) and activated PCCs (aPCCs). In this review we evaluate the role of PCCs and aPCCs in the reversal of dabigatran anticoagulation and consider which tests are appropriate for monitoring coagulation in this setting. Pre-clinical studies, small clinical studies and case reports indicate that PCCs and aPCCs may be able to reverse dabigatran-induced anticoagulation in a dose-dependent manner. However, dosing based on coagulation parameters can be difficult because available assays may not provide adequate sensitivity and specificity for measuring anticoagulation induced by dabigatran or the countering effects of PCCs/aPCCs. In addition, PCCs or aPCCs can potentially provoke thromboembolic complications. Despite these limitations and the fact that PCCs and aPCCs are not yet licensed for dabigatran reversal, their use appears to be warranted in patients with life-threatening haemorrhage if idarucizumab is not available.

Full Text

Duke Authors

Cited Authors

  • Grottke, O; Aisenberg, J; Bernstein, R; Goldstein, P; Huisman, MV; Jamieson, DG; Levy, JH; Pollack, CV; Spyropoulos, AC; Steiner, T; Del Zoppo, GJ; Eikelboom, J

Published Date

  • April 28, 2016

Published In

Volume / Issue

  • 20 / 1

Start / End Page

  • 115 -

PubMed ID

  • 27125504

Pubmed Central ID

  • 27125504

Electronic International Standard Serial Number (EISSN)

  • 1466-609X

Digital Object Identifier (DOI)

  • 10.1186/s13054-016-1275-8

Language

  • eng

Conference Location

  • England